Kelun is a highly specialized innovative pharmaceutical group with annual sales revenue of over 40 billion RMB and has more than 100 subsidiaries (branches) at home and abroad, including Sichuan Kelun Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Klus Pharma Inc. (Kelun, USA), Kelun KAZ Pharmaceutical Co., Ltd (Kelun, Kazakhstan), Sichuan Kelun Medicine & Trade Group Co., Ltd., etc. In 2017, Kelun ranked 155th in China's top 500 manufacturing enterprises, and the comprehensive strength ranked top three in China's pharmaceutical industry. In 2018, with the global advantages in IV solutions, Kelun was awarded as Single Champion Demonstration Enterprise of National Manufacturing Industry.
Sichuan Kelun Pharmaceutical Co., Ltd. was listed on the Shenzhen Stock Exchange in June 2010. After being listed in the market, Kelun immediately initiated a 10 billion yuan industrial investment plan and carry out a development strategy driven by "Three Engines and Internal Growth". The first engine is to maintain Kelun's leading position in the field of IV solutions through continuous industrial upgrading and product variety adjustment. The second engine is to build the competitive advantage from intermediates, APIs to formulations through the innovative development and utilization of high-quality natural resources. The third engine is to accumulate the ultimate driving force for the enterprise development through the construction of the R&D system and diversified technological innovation.
In the field of IV solutions, Kelun has achieved comprehensive industrial upgrading, and possessed profitability in high-end manufacturing and new materials, taking the lead in technology innovation and quality benchmarks. To ensure product quality and safety, Kelun established a grand quality management system from R&D, manufacturing, and logistics transport to end-use. Its leading products have achieved batch exports, enjoying a good reputation in over 50 countries and territories. The collapsible Uniflex® PP-bottle, a self-developed product of Kelun Pharmaceutical, with more than 20 patents, is an original invention both at home and abroad, and has won the State Science and Technology Advancement Award. Compared with traditional IV solutions, Uniflex® is safer and has higher cost performance. Moreover, its application considerably reduces energy consumption and protects the environment. This product represents the development direction of future IV solution products.
In the area of antibiotics, Kelun expanded to the west and set up Yili Chuanning Biotech Co., Ltd. which produces erythromycin thiocyanate and cephalosporin intermediates. Kelun has been approved to build State Environmental Protection Engineering Center for Harmless Treatment and Resource Utilization of Antibiotic Residues through R&D, upgrading and optimization, innovative cooperation, and introduction of advanced technology and equipment at home and abroad. This has solved the source problems in the antibiotic industry.
Kelun has successively invested billions of yuan in R&D and innovation ever since its founding, established the National Postdoctoral Scientific Research Workstation, received 13 awards of "State Key New Products", undertaken 12 major scientific and technological projects for "Significant New Drug Development", 1 project of "National Scientific and Technical Supporting Programs" and 1 "National Scientific and Technical China Aid Project". As of now, Kelun has applied for more than 4,000 patents, wherein over 2,000 patents got licensed. Moreover, Kelun has initiated the development of more than 500 critical drugs in multiple fields, such as tumors, bacterial infection, parenteral nutrition, etc. The license out of innovation patents of overseas markets indicates that Kelun's drug research and development has entered into a virtuous circle of "generics promote innovation, innovation drives the future" and then successfully marched towards the international market.
To make the most of medical talents and other competitive resources at home and abroad, Kelun established a research and development system including the Chengdu Research Institute at its core, Suzhou and Tianjin research branches and an American research branch serving as two parts of the R&D system. This is a new kind of R&D mode, which is led by domestic institutes with the help of foreign technology. Now, Kelun is one of the leading Chinese pharmaceutical enterprises with outstanding innovation capability.
With the enterprise objective "Pursue Truth in Science and Kindness in Ethics", Kelun has donated over two hundred million RMB for the social public welfare, the Guangcai Program and charity, presenting Kelun's wealth concept and sense of social justice, exhibiting a good and healthy developmental image of an outstanding private enterprise under the condition of the market economy.